ROS1 and non-small cell lung carcinoma: These observations underscore the association between ROS1 rearrangement and elevated PD-L1 expression in NSCLC, aligning with existing literature that points to the abnormal activation of oncogenes, including ROS1 and ALK, as a driving force behind PD-L1 expression in this disease context (18, 35).